NM_000237.3:c.1421C>G

Variant summary

Our verdict is Likely benign.
-2 Likely Benign
-7
-6
-1
0
+5
+6
+9
+10
B
LB
VUS
LP
P
The variant received -2 classification points (ACGS-UK Somatic Oncogenicity v2025). O2_ModerateB1_Strong

The NM_000237.3(LPL):c.1421C>G (p.Ser474*) variant causes a stop gained change involving the alteration of a non-conserved nucleotide. This is a loss-of-function variant that does not trigger NMD. The gene LPL is a tumor suppressor gene (CancerMine: 2 TSG, 6 oncogene, 2 driver citations). The gene LPL is a known oncogene (CancerMine: 2 TSG, 6 oncogene, 2 driver citations). The gene LPL is a cancer driver gene (CancerMine: 2 TSG, 6 oncogene, 2 driver citations). The variant allele was found at a cumulative frequency of 0.0968 (AC=156,015) in the gnomAD database across 1,611,322 control chromosomes, including 7,879 homozygotes. The grpmax filtering allele frequency (95% CI) is 0.119. In-silico predictor (BayesDel (noAF)) classifies this variant as likely damaging/oncogenic. Splicing prediction tools (SpliceAI) predict no significant impact on normal splicing. Variant has been reported in ClinVar as Benign/Likely Benign (★★). The variant has been observed in cBioPortal in 3 samples across 2 studies and 3 cancer types; somatic enrichment level: SUPPORTING_LOW (Observed in a small number of cBioPortal cases.).

Frequency

Genomes: 𝑓 0.090 ( 610 hom., cov: 32)
Exomes 𝑓: 0.098 ( 7269 hom. )

Consequence

LPL
NM_000237.3 stop_gained

Scores

5
1
1

Clinical Significance

Benign criteria provided, multiple submitters, no conflicts B:11

Conservation

PhyloP100: 0.429

Publications

451 publications found
Variant links:
Genes affected
LPL (HGNC:6677): (lipoprotein lipase) LPL encodes lipoprotein lipase, which is expressed in heart, muscle, and adipose tissue. LPL functions as a homodimer, and has the dual functions of triglyceride hydrolase and ligand/bridging factor for receptor-mediated lipoprotein uptake. Severe mutations that cause LPL deficiency result in type I hyperlipoproteinemia, while less extreme mutations in LPL are linked to many disorders of lipoprotein metabolism. [provided by RefSeq, Jul 2008]
LPL Gene-Disease associations (from GenCC):
  • familial lipoprotein lipase deficiency
    Inheritance: AR Classification: DEFINITIVE, STRONG Submitted by: Laboratory for Molecular Medicine, Genomics England PanelApp, Natera, Labcorp Genetics (formerly Invitae), G2P, Ambry Genetics
  • hyperlipidemia, familial combined, LPL related
    Inheritance: AD, SD, Unknown Classification: STRONG, LIMITED Submitted by: Genomics England PanelApp, PanelApp Australia, Natera

Genome browser will be placed here

new If you want to explore the variant's impact on the transcript NM_000237.3, check out the Mutation Effect Viewer. This is especially useful for frameshift variants or if you want to visualize the effect of exon loss / intron retention.

Classification according to ACGS-UK Somatic Oncogenicity v2025

Classification was made for transcript:

Our verdict: Likely_benign. The variant received -2 points.

O2Null variant in tumour suppressor gene
Non-NMD frameshift: LoF oncogenic mechanism, end-terminal — O2 moderate (+2); Use caution in the presence of multiple transcripts; Gene confirmed as TSG in CancerMine (TSG: 2 citations, oncogene: 6 citations, driver: 2 citations).; Frameshift/stop-gained. NMD predicted: false. LoF mechanism: true. Downstream pathogenic count: 0.
B1High frequency in general population
GnomAD effective popmax AF >1% — B1 stand-alone benign; GnomAD effective popmax AF = 0.119 — exceeds 1% threshold (B1 applied)

Variant Effect in Transcripts

Automated classification analysis was done for transcript: NM_000237.3. You can select a different transcript below to see updated classification assignments.

RefSeq Transcripts

LPL NM_000237.3
MANE Select
HGVSc / HGVSpc.1421C>Gp.Ser474*
Exon rankExon 9 of 10
stop_gained
Prot: NP_000228.1UniProt: P06858

Ensembl Transcripts

LPL ENST00000650287.1
MANE Select
HGVSc / HGVSpc.1421C>Gp.Ser474*
Exon rankExon 9 of 10
stop_gained
Prot: ENSP00000497642.1UniProt: P06858
LPL ENST00000965928.1
HGVSc / HGVSpc.1421C>Gp.Ser474*
Exon rankExon 11 of 12
stop_gained
Prot: ENSP00000635987.1UniProt: P06858
LPL ENST00000965929.1
HGVSc / HGVSpc.1418C>Gp.Ser473*
Exon rankExon 9 of 10
stop_gained
Prot: ENSP00000635988.1UniProt: A0ACI8VCL6

Frequencies

Allele frequencies (AF), counts (AC/AN), homozygotes and coverage

Common (AF > 0.05 / Hom > 5)
Rare (AF ≤ 0.0001 / Hom ≤ 1)
Global population databases 6 sources
GnomAD3 genomes
AF: 0.0902
AC:13720
Hom:611
AN:152082
Cov:32
GnomAD2 exomes
AF: 0.0922
AC:23148
AN:251182
GnomAD4 exome
AF: 0.0975
AC:142308
Hom:7269
AN:1459122
Cov:31
GnomAD4 genome
AF: 0.0901
AC:13707
Hom:610
AN:152200
Cov:32
TOPMed (Bravo)
AF: 0.0879
AC:23273
Hom:1103
AN:264690
ALFA (dbGaP/dbSNP Allele Frequency Aggregator)
AF: 0.0990
AC:12022
Hom:621
AN:121420
Local & regional cohorts 11 sources
ABraOM SABE-WGS-1171
AF: 0.0944
AC:221
Hom:15
AN:2342
ChinaMAP Phase 1
AF: 0.0912
Denmark Genome
AF: 0.120
AC:36
AN:300
ESP6500 (Exome Variant Server)
AF: 0.0863
AC:1123
AN:13006
GenomeAsia100K
AF: 0.100
AC:346
AN:3478
Korea4K (4,157 Koreans)
AF: 0.116
AC:840
AN:7234
Qatari Genome
AF: 0.0825
AC:165
AN:2000
ToMMo 61KJPN (+60KJPN MNV)
AF: 0.131
AC:16028
Hom:1040
AN:122780
Turkish Variome
AF: 0.104
AC:698
Hom:43
AN:6708
UK10K
AF: 0.107
AC:811
AN:7562
WBBC (Westlake BioBank for Chinese) pilot
AF: 0.102
AC:917
Hom:53
AN:8960
Showing 17 sources

Case/control cohorts

CohortCasesControls
AFACANAFACAN
ASC
(Autism)
0.0963 *107011108 0.100 *176817610
BipEx
(Bipolar disorder (including schizoaffective))
0.0976 277328420 0.0971 280228844
Epi25
(Epilepsy)
0.101 423341946 0.0927 617066536
SCHEMA
(Schizophrenia)
0.105 13524128696 0.107 21829203540
Showing 4 cohortsAllele count / allele number. AF is computed from the counts for ASC (not provided by the source).

ClinVar

ClinVar submissions
Significance:Benign
Revision:criteria provided, multiple submitters, no conflicts
View on ClinVar
Pathogenic
VUS
Benign
Condition
-
-
3
not provided (3)
-
-
3
not specified (3)
-
-
2
Hyperlipoproteinemia, type I (2)
-
-
1
Cardiovascular phenotype (1)
-
-
1
Hyperlipidemia, familial combined, LPL related;C0023817:Hyperlipoproteinemia, type I (1)
-
-
1
LPL-related disorder (1)

Computational Scores

AlphaGenome AVI
Pathogenic46
BayesDel_addAF
Pathogenic0.17D
BayesDel_noAF
Pathogenic0.57
CADD
Pathogenic46
DANN
Uncertain1.0
Eigen
Pathogenic0.99
Eigen_PC
Pathogenic0.83
FATHMM_MKL
Benign0.70D
GPN-Star LLR
N/A-9.4
GPN-Star score
N/A9.4
PhyloP100
Benign0.43
Showing 11 of 11 scores

Splicing Scores

DS_DG_spliceai
Uncertain0.20
Position offset: -3
Pangolin (max)
Uncertain0.23
Pangolin loss
Uncertain0.23
Position offset: 6
SpliceAI score (max)
Uncertain0.20
Details are displayed if max score is > 0.2
Showing 4 of 4 scores

Find out detailed SpliceAI scores and Pangolin per-transcript scores at spliceailookup.broadinstitute.org

MaxEntScan Visualizer can be used to analyze the impact of this mutation on the neighboring sequence.

MaveDB functional evidence

MaveDB is a public repository of laboratory assays that test the effect of thousands of variants at once — treat this as supporting research data and interpret it with great caution; it is not a clinical classification.

No MaveDB functional evidence found for this variant.

Publications

Other links and lift over

For research and educational, non-commercial use only. Not for clinical or diagnostic use. GeneBe does not provide medical advice. Data use for AI modeling is prohibited: if used, the cost is $0.001 per byte of downloaded uncompressed data.